Somatic mutations in pulmonary arterial hypertension: primary or secondary events?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. The genomic complexity underlying pulmonary arterial hypertension: from mendel to networks.American journal of respiratory and critical care medicine · 2014
   Article
2. Connectivity map analysis of nonsense-mediated decay-positive BMPR2-related hereditary pulmonary arterial hypertension provides insights into disease penetrance.American journal of respiratory cell and molecular biology · 2012
   Article
3. BMPR2 mutations and endothelial dysfunction in pulmonary arterial hypertension (2017 Grover Conference Series).Pulmonary circulation
   Article

Corrections and comments

• Comment on
  Somatic chromosome abnormalities in the lungs of patients with pulmonary arterial hypertension.2010

Authors and funding

3 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as